Drug Safety Monitoring Service in Developing Organizations/Manufacturers of Drugs for Veterinary Use
| Autor: | Anna V. Morozova, Nadezhda P. Biryukova, Vera V. Napalkova, Feed |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Drug
Service (business) monitoring studies of drug safety QH301-705.5 media_common.quotation_subject Legislation General Medicine post-registration studies medicine.disease side effects Pharmacotherapy pharmacovigilance medicine adverse reactions Business Medical emergency Biology (General) Medical prescription Adverse effect media_common Safety monitoring |
| Zdroj: | Российский паразитологический журнал, Vol 13, Iss 2, Pp 73-81 (2019) |
| ISSN: | 2541-7843 1998-8435 |
| DOI: | 10.31016/1998-8435-2019-13-2-73-81 |
| Popis: | The danger of animal complications due to drug therapy increases the responsibility of developers/manufacturers for the safety of medicinal products for veterinary use, including those in civilian circulation. At the time of making a decision on the state registration of a drug, information obtained during its preclinical and clinical studies on undesirable reactions and side effects cannot be complete, since these studies are limited to a small number and similarity of experimental animals and a relatively short duration of experiments. In addition, with long-term use of the drug may be delayed adverse side reactions that can occur months and years after exposure of the drug to a living organism. Considering this, the pharmacovigilance system should function effectively in the producer (or developer) of the drug, the main task of which is monitoring monitoring of drug safety during the pre-registration period, tracking and analyzing data on the effect of the drug when it is in public circulation, and taking adequate measures to prevent adverse effects of drug therapy. As a result of the analysis, data on regulatory and methodological documents on the organization of monitoring the safety of pharmacological drugs were systematized, recommendations prepared with the provisions of international and domestic legislative regulatory and information documents related to the methodology of organizing pharmacovigilance and monitoring drug safety were prepared. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|